Get started

Gapdown

INFRATEL ::: LONGInstrument: INFRATEL Time frame: 3 hours indicators: Stochastics: bearish PSAR: bearish My analysis: CMP: 152.75 Expecting INFRATEL to gap down / sink to 145 - 143.70 on Monday. Once it starts retracing back upwards would like to buy above 143.70 to 145 keeping the SL below the low of the day for target 153.75 RISK DISCLOSURE: Technical analysis of FOREX and INDIAN MARKETS. We are not SEBI REGISTERED ANALYSTS The views expressed here are for our record purposes only. Please consult your personal financial advisor before investing. We are in no way responsible for your profits/losses what so ever.
ILong
by ajithchand-bhandaari
CUMMINSIND GAP DOWN AND BOUNCEInstrument: CUMMINSIND Time frame: 4 hours indicators: Stochastics: bearish PSAR: bearish My analysis: Expecting CUMMINSIND to gap down / sink to 371 - 354 on Monday. Once it starts retracing back upwards would like to buy above 366 to 371 keeping the so below the low of the day for targets 379 - 386. RISK DISCLOSURE: Technical analysis of FOREX and INDIAN MARKETS. We are not SEBI REGISTERED ANALYSTS The views expressed here are for our record purposes only. Please consult your personal financial advisor before investing. We are in no way responsible for your profits/losses what so ever.
NSE:CUMMINSIND
by ajithchand-bhandaari
BANKNIFTY ::: GAP DOWN ???DATE: 20 APRIL 2020 TIME: 20:05 INSTRUMENT: BANKNIFTY : F&O TIMEFRAME: 1HR CMP: 20488.55 INDICATOR PSAR: BEARISH INDICATOR STOCHASTICS: BEARISH EXPECTING A GAP DOWN WHEN THE MARKET OPENS TOMORROW. SELL BELOW: 20429 STOP LOSS:20577 TARGET 01:20331 TARGET 02: 20259 Technical analysis of FOREX and INDIAN MARKETS. We are not SEBI REGISTERED ANALYSTS The views expressed here are for our record purposes only. Please consult your personal financial advisor before investing. We are in no way responsible for your profits/losses what so ever.
NSE:BANKNIFTYShort
by ajithchand-bhandaari
3
Update: 1 gap down left and a few gaps up $TSLA Update on my previous idea: the gap up has been closed, 2 gaps down have been closed with more gaps up created. We are closing in on the 3rd gap down which also coincide with the golden 0.618 fib and will very likely be closed next week. I'm expecting a rebound in the days leading to the Q1 delivery numbers announcement with maybe the date given for battery day the last week of March too. Bonus added: a gap even lower from October that could be closed as most countries already in hidden recession are now closing everything to prevent the virus from spreading and trying to flatten the curve.
NASDAQ:TSLAShort
by Nooblade
2
S&P500 Gaps Down -4%#sp500 #spx #sp1! – S&P500 futures have once again gapped down as markets reopened for trading tonight, currently down -137 points for a -4.6% loss. Price is now below the 50% Fibonacci retracement level which is the midpoint between the low seen in October 2018 and the high made in February 2020. 50% retracements after a large/long uptrend are generally viewed as healthy corrections within the overall price advance and represent good buying opportunities, while further declines below the 50% Fib indicate that the previous bull trend is at risk of turning into a bear trend, at least in the short-term. A sign that the bull trend is likely over and a new short-term bear market is forming would be a move below the 61.8% fib level which is the golden ratio retracement. Should price fail to regain the 50% level this week, the likely target will be the 61.8% fib shown in red at 2729 which would be another -3% decline from current price. Also in the chart is a broadening wedge pattern, also know as a megaphone pattern due to its shape resembling a megaphone. A broadening wedge is a range where price is holding between two diverging trendlines, or lines that are moving apart. These lines are where traders can expect price to trade between, or find support and resistance at. A break above the upper wedge line is viewed as bullish and the beginning of a new uptrend, while a break below the lower wedge line is viewed as bearish and the beginning of a new downtrend. In October of 2018 price broke above the upper wedge line and began the climb to new all-time highs peaking in February of 2020. While this move was viewed as bullish uptrend continuation, price has now fallen back within the wedge indicating that the previous break above it was a blowoff top rather than uptrend continuation. Now that price is back within the broadening wedge pattern, the potential for a test of the lower wedge line is now a possibility. For now the level to watch this week, or possibly even on Monday, is the 61.8% Fibonacci retracement level highlighted in red. A move below this level is likely this week considering the coronavirus fear currently gripping markets and its impact on not just the US economy, but also the global economy. This weekend saw the situation deteriorate in regard to the virus and the climbing infection and death rates in the US, as well as new fears launched by Saudi Arabia as they attempt to put US shale out of business by increasing oil production which as of now as oil trading -22% lower than Fridays close. It appears as though this week could be even more volatile than the previous two weeks, which both saw record price moves, moves not seen since the global financial crisis in 2008. We may be in for another emergency rate cut by the Federal Reserve ahead of their planned meeting which takes place March 17th-18th. Two emergency rate cuts within two weeks would be another new milestone and further evidence that the US economy is teetering on the edge of financial disaster ahead of what appears to be an inevitable slowdown in economic activity.
SShort
by PrepForProfit
Oil Gap Down Open To Target Level#oil #cl1! – Oil saw a gap down tonight to the target area shown in my previous chart shared this morning, and for now is attempting to hold at the lower parallel channel line that I drew which was an anticipated support level based on recent price trend. Price opened at $32.87 which is a -20.37% decline from Friday’s closing price of $41.28. Still very early in futures trading, but I’m expecting volatility in price while waiting for US traders to digest this move overnight and make their move tomorrow at market open before sharing another update. If Saudi Arabia is determined to flood the market with oil in attempt to put US shale oil out of business, we can probably expect them to continue beating down price this week with talk of more oil output on their end in the coming weeks.
NYMEX:CL1!Short
by PrepForProfit
S&P 500 Futures Gap Down#sp1! - S&P500 futures gapped down on the first night of trading following the worst week for stocks since the financial crisis. A continued push down was expected after more negative news flowed out during the course of the weekend, most notably in the U.S. where we saw the first Covid19 death, as well as localized quarantines and self-isolation being recommended in a few states. The main levels to watch for an indication of what Monday's trend will be for stocks when markets re-open are shown in orange. The upper orange line is where Thursday's price closed and where Friday's price were unable to close above. The lower orange line is where price bottomed on Friday. A move above the upper line would indicate that traders are attempting to form a bottom, or relief rally; a push below the lower orange line would indicate that traders aren't done selling the Covid19 fear as new lows are continuing to be made. The PPO is still in a hard decline, while the RSI is attempting to level off in oversold territory, though the RSI could remain oversold for quite some and doesn't necessarily mean that prices are prime to buy just yet. Judging by the continued deterioration of the situation, and lack of containment world-wide, we can expect traders to be hesitant to push prices higher until/unless the Federal Reserve and other global central banks step in with lower rates. Even then, the reactionary bounce on that potential event will likely be short-lived as the overall outbreak looks to be just kicking in to gear. Good luck out there this week, more updates on SP500 after the markets close tomorrow, or in the early morning if there is a significant price move or updated Covid19 news.
SShort
by PrepForProfit
CAC 40 At Crucial Support CAC40 opened With massive Gapdown trapping all the bulls at higher level This must have forced the small leveraged Trader to exit Their Position at the lower rates forcing the index downwards. Index can Face Heavy Selling Pressure from tops All the trapped brave Traders who didn't exit their position in today's fall will be waiting for their prices on the higher side. So Sell on rise pattern could be seen in this index CAC40 Is currently trading Below its 100 EMA at crucial Support Level of previous swing low. Fresh Sell Off Can be Seen Below The swing low till 5720 Levels which is 200 EMA and 4th Decembers Low.
TVC:CAC40
by TradingOx
1
S&P500 futures opened the week with a GAP DOWNAs expected with last week’s idea post, the correction phase is underway, and it is rather massive with a Gap Down of -1% to open the week. IF the momentum continues, this is very bad news for the equity markets. The current outcome and probable continued momentum is triggered by the weekend surprise of Northern Italy COVID-19 outbreak and lockdown, as well as South Korea’s escalating infections and deaths, including a national highest alert. These two events were not expected and the two countries have over taken Singapore as the top gunners, after China. On the heels of topping out last week, the technicals for this chart is very bearish, and would likely continue to be so for the rest of the week. In the last year, this is the second Monday Gap Down in the /ES futures Of more than 1%.
CME_MINI:ES1!Short
by Auguraltrader
Pinterest sideways move till earnings reportHi all, There is no particular reason for PINS to make a move at this moment. In my opinion it just follows the market's trend and i am expecting it to accumulate on the upward channel till next earnings report. At this time i am expecting a gap up or gap down depending on the results. To be honest it's a very difficult trade but i think that since the market is doing well that they are not going to risk another bad quarter and they somehow show the results in a positive way and keep anything bad for another quarter.
NYSE:PINS
by Philoslother
MCK - Earnings Miss, Channel IntactMCK had a poor earnings report on October 30th but despite the falling price it still managed to hold the ascending channel. The stock price is right at the gap resistance level but with the stock trying to escape an oversold condition it looks to have a lot more room to rise. I would be aiming for the resistance line of the ascending channel but $147.20 is the 61.8% Fibonacci Extension level which would be a good level to look for a pause in the rally.
NYSE:MCKLong
by Chartimistic
SHAK - Just a little overdoneStock sold off due to their earnings report. Honestly, I don't think the report was so bad to deserve a +20% selloff. If you look at the other burger stocks, all dealing with the same issues, most of those stocks held up today, even being green. The selloff today held around the 61.8% Fibonacci Retracement level from the December low to the recent September highs. I am keeping an eye on this stock to see how these levels hold. I think this should start bouncing back as the weak hands & profit-takers close their positions.
NYSE:SHAKLong
by Chartimistic
$NXTC Still Has Potential$NXTC got hammered on Monday after reporting disappointing data over the weekend. While the stock closed down 52%, it could have been a lot worse and the stock did bounce on the day. This signals that buyers were stepping in. Here's what happened: Thinly traded NextCure (NASDAQ:NXTC) closed down 52% on modest volume on the heels of updated results from the first part of its Phase 1/2 clinical trial evaluating NC318, a Siglec-15 (S15)-targeting monoclonal antibody, in patients with solid tumors. The data were presented at the SITC Annual Meeting in Maryland. Seven dose cohorts (8 mg - 1,600 mg every two weeks) were assessed, predominantly in patients with non-small cell lung cancer (n=13), ovarian cancer (n=7), melanoma (n=7), breast cancer (n=4) and colorectal cancer (n=3). All NSCLC patients failed to respond to PD-1 inhibitor treatment (median of four prior lines of therapy). Durable responses were observed, including one complete response (ongoing at week 55), one partial response (ongoing at week 28), four NSCLC patients with stable cancer (ongoing at weeks 16 - 40) and 14 participants overall with stable cancer (ongoing at weeks 16 - 42). On the safety front, 15 patients remain on study implying a discontinuation rate as high as 44% (n=15/34). Most treatment-emergent adverse events (TEAEs) were mild/moderate. There were three serious TEAEs, one case of episcleritis/uveitis and two cases of pneumonitis. The company has initiated the Phase 2 portion which will evaluate 400 mg administered every two weeks in ~100 patients with NSCLC, ovarian, head and neck and triple-negative breast cancers. The primary endpoints are safety and tolerability. Secondary endpoints include efficacy measures. Preliminary data should be available by late Q4 2020. NextCure, Inc., a biopharmaceutical company, engages in discovering and developing immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase I/II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, is a novel immunomedicine designed to block immune suppression for the treatment of ovarian cancer, non-small cell lung cancer, and renal cancer. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules that targets a novel member of the B7-family of immunomodulatory proteins; and an antibody in preclinical development targeting an immune modulator that is expressed in inflamed tissue and the tumor microenvironment in various tumor types. NextCure, Inc. has a license agreement with Yale University; and a research and development collaboration with Eli Lilly and Company. The company was founded in 2015 and is based in Beltsville, Maryland. As always, trade with caution and use protective stops. Good luck to all!
NASDAQ:NXTCLong
by InsiderFinancial
Market May Have Overreacted On $LPCNIt's always risky playing biotech small caps. The stock could collapse at any minute or skyrocket the next. $LPCN looks quite interesting after dropping 70% yesterday. What caught our attention is that the stock opened on the lows and rallied from there. Some bottom feeders were in the stock and that's a good sign for those that are looking for new stocks to trade. Here's what happened: Lipocine (NASDAQ:LPCN) has received a third Complete Response Letter (CRL) from the FDA regarding its refiled marketing application for testosterone replacement therapy candidate Tlando. This time the agency cited one issue (instead of four the first time): the efficacy trial failed to meet the three secondary endpoints for maximal testosterone concentrations (Cmax). The company intends to request a meeting with the agency to clarify a path forward. The company received the first CRL in June 2016 and the second in May 2018. Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men’s and women’s health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company’s pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah. As always, trade with caution and use protective stops. Good luck to all!
NASDAQ:LPCNLong
by InsiderFinancial
Traders Bought The Dip On $UPLD$UPLD saw a nice bounce on Friday off the lows as traders bought the dip after $UPLD reported disappointing earnings. Here are the highlights of that report: Upland Software (NASDAQ:UPLD): Q3 Non-GAAP EPS of $0.52 misses by $0.06; GAAP EPS of -$0.50 misses by $0.18. Revenue of $55.1M (+48.5% Y/Y) misses by $0.32M. $UPLD is now trading at just 13x earnings. Credit Suisse came out last week before earnings and gave $UPLD a $48 price target. Upland Software, Inc. provides cloud-based enterprise work management software in the United States, the United Kingdom, Canada, and internationally. The company offers a family of software applications under the Upland brand in the areas of information technology, process excellence, finance, professional services, and marketing. Its software applications address enterprise work challenges in various categories comprising customer experience management, sales enablement solutions, professional services automation, project and financial management, enterprise knowledge management, secure document services, and document lifecycle automation. The company sells its products through a direct sales organization, as well as through an indirect sales organization that sells to distributors and value-added resellers. It serves customers across a range of industries, including financial services, retail, technology, manufacturing, legal, education, consumer goods, media, telecommunications, government, food and beverage, healthcare, and life sciences, as well as non-profit organizations. The company was formerly known as Silverback Enterprise Group, Inc. and changed its name to Upland Software, Inc. in November 2013. Upland Software, Inc. was founded in 2010 and is headquartered in Austin, Texas. As always, trade with caution and use protective stops. Good luck to all!
NASDAQ:UPLDLong
by InsiderFinancial